2020 Vision For Biopharma
Welcome To The New Roaring Twenties
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
You may also be interested in...
Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry.
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...